Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded the Company of the Year Award at the European Mediscience Awards 2014. The Company of the Year Award is awarded to a company who has gained recognition from analysts and investors for management, financial stability, and growth with a well-defined strategy to deliver its key financial, ethical and social ambitions.
"Sobi is truly honoured to be recognised by the Mediscience community", says Geoffrey McDonough, President and CEO of Sobi.
The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. The event recognises the importance of the capital markets to fund growth and innovation. The awards celebrate, amongst others, the breakthrough of the year, the best technology and the most significant contribution to the industry.
Stockholm-based Sobi is an international specialty healthcare company dedicated to rare diseases. It has a diversified and growth-oriented commercial product portfolio with key therapeutic areas being Inflammation and Genetics and Metabolism, and three late stage biological development projects within Haemophilia and Neonatology. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing which have been validated by leading industry partners
